Aisling Capital LLC lessened its position in shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) by 92.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 210,000 shares of the specialty pharmaceutical company’s stock after selling 2,500,000 shares during the period. Pernix Therapeutics comprises 0.3% of Aisling Capital LLC’s holdings, making the stock its 11th largest position. Aisling Capital LLC’s holdings in Pernix Therapeutics were worth $1,558,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. California Public Employees Retirement System grew its holdings in shares of Pernix Therapeutics by 121.0% in the 3rd quarter. California Public Employees Retirement System now owns 82,838 shares of the specialty pharmaceutical company’s stock valued at $261,000 after acquiring an additional 45,358 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Pernix Therapeutics in the 2nd quarter valued at about $188,000. Virtu KCG Holdings LLC grew its holdings in shares of Pernix Therapeutics by 167.8% in the 2nd quarter. Virtu KCG Holdings LLC now owns 76,964 shares of the specialty pharmaceutical company’s stock valued at $309,000 after acquiring an additional 48,225 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Pernix Therapeutics by 16.2% in the 2nd quarter. Vanguard Group Inc. now owns 402,423 shares of the specialty pharmaceutical company’s stock valued at $1,617,000 after acquiring an additional 56,182 shares in the last quarter. Hedge funds and other institutional investors own 16.35% of the company’s stock.

Pernix Therapeutics Holdings Inc (NASDAQ PTX) opened at $2.21 on Monday. The firm has a market capitalization of $26.07, a PE ratio of -0.15 and a beta of 1.64. The company has a quick ratio of 0.91, a current ratio of 0.99 and a debt-to-equity ratio of -0.80. Pernix Therapeutics Holdings Inc has a 1-year low of $2.00 and a 1-year high of $7.15.

TRADEMARK VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/02/12/aisling-capital-llc-lowers-holdings-in-pernix-therapeutics-holdings-inc-ptx.html.

Pernix Therapeutics Company Profile

Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.

Want to see what other hedge funds are holding PTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pernix Therapeutics Holdings Inc (NASDAQ:PTX).

Institutional Ownership by Quarter for Pernix Therapeutics (NASDAQ:PTX)

Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.